Quest Diagnostics, Inc. Quarterly Earnings on Deck

S&P 500 (NYSE:SPY) component Quest Diagnostics, Inc. (NYSE:DGX) will unveil its latest earnings on Tuesday, October 25, 2011. Quest Diagnostics provides diagnostic testing, information, and services to patients, physicians, and others.

Quest Diagnostics, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for net income of $1.11 per share, a rise of 5.7% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from $1.13. Between one and three months ago, the average estimate moved down. It also has dropped from $1.12 during the last month. Analysts are projecting profit to rise by 3.4% versus last year to $4.22.

Past Earnings Performance: Last quarter, the company saw profit of $1.12 per share versus a mean estimate of net income of $1.12 per share. This comes after two consecutive quarters of exceeding expectations.

Investing Insights: has a Stock Chart Technical Analysts Dream About.

Wall St. Revenue Expectations: Analysts are projecting a rise of 1.6% in revenue from the year-earlier quarter to $1.89 billion.

Analyst Ratings: Analysts seem relatively indifferent about Quest Diagnostics with 16 of 20 analysts surveyed maintaining a hold rating.

A Look Back: In the second quarter, profit fell 16.2% to $163.1 million ($1.02 a share) from $194.6 million ($1.07 a share) the year earlier, meeting analyst expectations. Revenue rose 1.5% to $1.9 billion from $1.87 billion.

Key Stats:

The company’s revenue has risen for two straight quarters. In the first quarter, the figure rose 0.9%.

Competitors to Watch: Laboratory Corp. of America Hldgs. (NYSE:LH), Clarient, Inc. (NASDAQ:CLRT), Psychemedics Corp. (NASDAQ:PMD), Bio-Reference Laboratories, Inc. (NASDAQ:BRLI), MEDTOX Scientific, Inc. (NASDAQ:MTOX), Celera Corporation (NASDAQ:CRA), Enzo Biochem, Inc. (NYSE:ENZ), Orchid Cellmark, Inc. (NASDAQ:ORCH) and RadNet Inc. (NASDAQ:RDNT).

Stock Price Performance: During July 26, 2011 to October 19, 2011, the stock price had fallen $6.51 (-11.7%) from $55.62 to $49.11. The stock price saw one of its best stretches over the last year between December 13, 2010 and December 22, 2010 when shares rose for eight-straight days, rising 7.1% (+$3.57) over that span. It saw one of its worst periods between August 15, 2011 and August 22, 2011 when shares fell for six-straight days, falling 6% (-$2.93) over that span. Shares are down $4.46 (-8.3%) year to date.

(Source: Xignite Financials)

Investing Insights: has a Stock Chart Technical Analysts Dream About.